前列腺癌诊断市场按产品类型、检测类型、最终用户、技术和应用划分－2025-2032年全球预测

预计到 2032 年，摄护腺癌诊断市场规模将成长 43.3 亿美元，复合年增长率为 14.60%。

关键市场统计数据
基准年 2024	14.5亿美元
预计年份：2025年	16.7亿美元
预测年份 2032	43.3亿美元
复合年增长率 (%)	14.60%

前列腺癌的诊断处于快速发展的生物医学科学与不断变化的临床实践模式的关键交汇点。近年来，诊断路径已从依赖单一检测法筛检工具发展为结合生物标记、分子平台、影像引导切片检查和先进成像系统的整合策略。因此，临床、商业和监管领域的相关人员正在重新评估如何更早地识别疾病、更准确地进行风险分层、减少不必要的侵入性操作，同时维持或改善治疗效果。

在此背景下，诊断创新正受到多种技术趋势的驱动。生物标记和套件的开发已从基础蛋白质检测发展到涵盖基因和分子检测套组，并通常结合先进的分析技术。 CT、MRI、PET 和超音波等影像系统正针对摄护腺应用进行最佳化，而切片检查技术的改善也持续影响组织采集策略。这些发展共同重塑了临床路径，并促成了更个人化的诊断和治疗方案。

随着传统模式的转变，实验室、医院、门诊手术中心和研究实验室都在调整工作流程和资本规划，以适应诊断技术的进步。临床团队积极采用新的检测方法和模式，而支付方和政策制定者则在重新评估医保覆盖框架和实践指南。本执行摘要深入分析了变革性转变、结构性阻力（例如关税的影响）、市场区隔资讯、区域动态、竞争对手的行动，并提出了切实可行的建议，以帮助领导者应对这一不断变化的环境。

新的多模态诊断策略、分散式检测以及不断变化的报销预期，正在从根本上改变前列腺癌的诊疗方式。

前列腺癌诊断领域正经历重大变革，这既得益于科学突破，也源自于商业需求。包括次世代定序和基于PCR的检测在内的分子诊断方法，已从小众研究工具转变为临床上用于风险分层和指南切片检查决策的重要工具。同时，先进的影像技术正与介入治疗流程更加紧密地结合，从而实现标靶切片检查并降低诊断的不确定性。

另一项重大转变是向多模态诊断演算法的转变，该演算法结合了生物标记、影像学和临床参数，以优化切片检查和治疗的患者选择。这种综合方法减少了过度诊断，并支持更精准的治疗路径。此外，随着门诊手术和诊断中心采用即时检测和更贴近患者的检测方式，诊断的去中心化程度正在提高，这改变了医院的转诊流程和资本投资决策。

为了适应新的诊断模式，监管和报销环境也在不断演变。支付方越来越关注基于价值的指标和真实世界证据，因此，临床效用（而不仅仅是分析性能）的证明变得尤为重要。因此，企业和临床团队必须将证据的生成与以结果为导向的终点指标结合。总而言之，这些转变正在加速从「一刀切」的筛检转向更符合患者风险状况和治疗目标的个人化诊断策略。

了解累积关税变更对医疗诊断采购和部署的营运、采购和供应链的连锁影响

政策变化和贸易行动可能对医疗设备和诊断供应链造成巨大的营运压力，而2025年关税调整的集中实施将产生一系列累积效应，需要密切关注。影响医疗设备、试剂和耗材的关税上调往往会增加诊断影像系统、切片检查设备和套件的到岸成本，进而影响医院、诊断中心和门诊手术中心的采购週期。当资本预算紧张时，决策者会优先考虑已证实有效的临床效用和成本效益，即使临床效益显而易见，也可能导致新设备的引进被推迟。

除了直接的成本影响外，关税还可能加速区域筹资策略和供应商多元化。製造商和买家可能会透过缩减某些生产活动、在不同地区寻找新的供应商或寻求优化关税分类来减轻关税的影响。此类应对措施通常需要一定的前置作业时间和投资，并可能暂时导致专用耗材或复杂影像处理组件的供应出现瓶颈。同时，供应商可能会调整定价模式、重新谈判销售合约或推出配套服务以维持市场进入。

重要的是，采购的不确定性会影响设备升级和培训计画的安排，从而对临床营运产生间接影响。因此，医疗系统可能会推迟一些不太紧急的技术升级，延长现有设备的使用寿命，或采取选择性部署策略，将新功能集中在卓越中心。对于诊断生态系统中的相关人员，积极监测供应链和政策，并制定紧急计画，对于应对关税波动带来的持续连锁反应至关重要。

透过整合产品、测试类型、最终用户、技术和应用维度进行細項分析，以发现策略重点和临床工作流程机会。

对细分市场的细緻分析揭示了临床需求、技术能力和最终用户背景如何交汇融合，从而创造差异化的商业机会。产品类型包括生物标记及套件、切片针及影像系统；生物标记及套件又细分为基因检测套组、分子诊断试剂套件及PSA检测；影像系统则细分为CT系统、MRI系统、PET系统及超音波系统。这种层级式的产品分类与检测类型细分相交，包括切片检查、影像检查、分子检测和PSA检测；影像检查又细分为CT、MRI、PET和超音波；分子检测则细分为NGS和PCR检测。从产品和检测类型两个角度来看，临床工作流程中最容易受到干扰的环节以及诊断和介入治疗流程整合能够带来最大临床效益的环节都至关重要。

检验最终用户细分，可以明确技术采纳路径。门诊手术中心、诊断中心、医院和研究诊所以及实验室的资本状况、吞吐量预期和临床范围各不相同，这些因素会影响技术选择和服务模式。以技术为中心的细分透过区分影像模式、免疫检测和分子诊断，进一步缩小了机会领域。影像模式包括CT、MRI、PET和超音波模式；免疫检测包括ELISA和RIA平台；分子诊断包括NGS和PCR技术。最后，应用细分——基因检测、早期诊断以及监测和追踪——针对不同的临床决策点和证据要求，其中监测应用通常需要纵向资料整合和标准化报告。

透过整合这些细分视角，相关人员可以更好地制定产品开发和商业化策略，这些策略考虑特定模式的工作流程整合、最终用户的采购行为以及初始诊断与纵向监测背景下不同的证据标准。

区域动态和基础设施差异将影响美洲、欧洲、中东和非洲以及亚太地区的前列腺癌诊断普及趋势。

区域动态持续影响着前列腺癌诊断技术的普及性和商业化策略。在美洲，医疗系统和私人机构正透过投资分子平台和先进影像系统来回应精准诊断的临床需求。相较之下，由于监管协调、国家筛检政策和医疗基础设施的差异，欧洲、中东和非洲的普及速度各不相同。

亚太地区正经历着都市区三级医疗机构快速采用新技术以及区域医院和诊断中心持续提升诊疗能力的双重挑战。该地区的需求既受到公共卫生措施的推动，也受到私人对诊断创新投资的驱动。在所有地区，门诊手术中心和诊断中心都是推广新型检测方法和分散医疗服务的关键管道。此外，一个地区的法律规范、报销环境和医疗服务提供者的分布情况，将决定新型生物标记检测法、成像系统和分子检测从临床研究到常规应用的转化速度。

因此，企业和医疗机构必须采取量身定制的策略，充分考虑基础设施成熟度、支付方期望以及临床指南的采纳情况。区域临床领导者、有针对性的证据产生以及灵活的部署模式对于将全球创新与本地实施实际情况相结合至关重要。

平台创新、策略伙伴关係和证据产生驱动的竞争格局将加速整合诊断解决方案和服务导向商业化进程。

前列腺癌诊断生态系统中的竞争者们持续投资于平台升级、策略伙伴关係以及与学术机构和临床中心进行实证合作。现有的医疗设备和诊断设备製造商不断改进CT、MRI、PET和超音波等影像系统，以更好地支援前列腺癌特异性方案和融合引导切片检查流程。同时，分子诊断专家们正在扩展检测项目，并简化次世代定序和基于PCR的检测流程，以促进更快、更整合的临床检测。

随着市场向涵盖生物标记检测、影像引导采样和下游分子分析的捆绑式诊断解决方案转型，套件製造商与影像及介入设备製造商之间的合作日益普遍。此外，将资本投资与培训、工作流程优化和售后资讯服务结合的服务模式，也越来越受到希望降低新技术应用复杂性的终端用户的青睐。研究机构和学术中心仍然是新型生物标记检验和临床效用研究的重要合作伙伴，协助商业公司建构更强有力的真实世界证据。

鑑于这些动态，成功的公司会优先考虑跨部门协作、协调一致的监管策略以及健全的上市后监测，以证明其临床价值。它们还会投资于可扩展的生产製造和多元化的供应链，以保持对市场的应对力，并降低政策和关税相关干扰的影响。

为技术开发商、医疗系统和投资者提供实际的策略行动，以加速技术应用、保障供应链并展现持久的临床价值。

行业领导者可以采取多项切实可行的措施来确保临床相关性和商业性韧性。首先，透过投资于能够显着降低诊断不确定性和后续流程负担的检测方法和检测手段，使产品开发与临床路径保持一致。其次，优先与临床中心和诊断网络建立伙伴关係，共同设计工作流程，简化实施过程，并显着改善切片检查和治疗决策的患者选择。透过这些措施，供应商可以缩短引进週期，并获得临床医生的认可。

第三，透过製造多元化、关键耗材二级供应商认证以及积极监测关税和贸易政策，增强供应链韧性。第四，采用灵活的商业模式，将资本设备与结果挂钩的服务、培训和数据分析相结合，以降低预算受限的终端用户的采用门槛。第五，投资生成符合支付方价值框架的真实世界证据。真实世界临床试验和基于註册登记的证据对于证明不同医疗环境中的临床效用尤为重要。

最后，要使本地市场策略与当地的监管和报销实际情况相符，同时利用卓越中心来展现临床和营运价值。领导者落实这些优先事项，将提高新诊断技术从创新到常规临床实践顺利过渡的可能性。

一项综合性的多方法研究途径，结合了临床访谈、文献综述、方案案例研究和供应链情境分析，提供了严谨的见解。

本报告整合了多种方法论的证据，以确保得出可靠且可重复的结论。主要研究包括对来自医院、门诊手术中心、诊断中心和实验室的临床专家、实验室主任和采购负责人进行结构化访谈，以了解他们对工作流程整合、采购标准和临床效用的在地化观点。次要分析包括对同行评审文献、临床指南、监管文件、成像和检测平台的技术规范以及製造商文件进行严格的审查，以明确技术能力和检验途径。

此外，我们也进行了案例研究和方案审查，以评估分子诊断、影像系统、生物标记和切片检查技术在实际应用中的情况。我们透过情境分析和专家咨询评估了供应链和政策影响，以确定应对关税变化和零件供应限制的可行营运方案。作为品质保证措施，我们将检验结果与已发表的临床结果进行交叉检验，并对来自多个来源的数据进行三角测量，以减少偏差并确保结果的一致性。

调查方法强调透明度和可重复性，包括记录访谈通讯协定、标註文献来源以及明确纳入二手文献的标准。这种多方法策略能够全面评估技术可行性以及影响不同医疗机构实施的实际障碍。

整合临床、营运和政策因素，以确定诊断创新是否能改善患者预后并实现永续的医疗保健价值。

前列腺癌的诊断正朝着更整合、个人化和实证的治疗模式发展。分子检测、精细化的生物标记检测法和影像系统的融合，使临床医生能够更明智地决定何时进行切片检查、如何进行靶向取样以及如何长期监测患者。同时，诸如关税驱动的供应链调整和不断变化的报销预期等营运压力，凸显了製造商和医疗保健系统战略灵活性的必要性。

展望未来，最具影响力的成功因素将是已证实的临床效用、便于工作流程的解决方案以及能够应对当地基础设施和政策实际情况的稳健商业化策略。技术提供者、临床机构和支付方之间的合作对于协调指导证据产生和应用的决策标准至关重要。透过专注于整合的诊断路径和可操作的证据，相关人员可以减少不必要的手术，优化资源利用，并最终改善以病人为中心的治疗效果。

总而言之，如果将技术创新与清晰的临床效用描述以及降低供应和政策相关风险的营运计划相结合，诊断生态系统将能够为前列腺癌治疗带来有意义的改进。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 整合人工智慧和机器学习技术，提高摄护腺癌诊断准确率，减少假阳性结果
• 利用液态生物检体平台对前列腺癌循环肿瘤DNA生物标记进行非侵入性检测
• 多参数磁振造影结合超音波融合技术的广泛应用提高了前列腺病变的早期诊断率。
• 开发和临床检验一种用于前列腺癌筛检的尿液外泌体和微型RNA检测方法
• 将PSMA PET影像引入常规诊断流程，以提高转移性前列腺癌的检出率
• 前列腺诊断中次世代定序技术的监管核准途径和报销策略
• 远端医疗的引入使得远距前列腺癌筛检和即时解读诊断结果成为可能。
• 开发照护现场诊断设备
• 诊断设备製造商与大学癌症中心合作，发现了前列腺癌的新型表观遗传生物标记。
• 将深度学习演算法与数位病理学结合，实现前列腺切片检查分级和预后评估的自动化

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 摄护腺癌诊断市场（依产品类型划分）

• 生物标记和套件
  • 基因检测套组
  • 分子诊断试剂套件
  • PSA检测
• 切片穿刺针
• 影像系统
  • CT系统
  • 磁振造影系统
  • PET系统
  • 超音波系统

第九章 前列腺癌诊断市场（依检测类型划分）

• 切片检查
• 影像检查
  • CT扫描
  • 磁振造影
  • PET扫描
  • 超音波
• 分子检测
  • NGS检测
  • PCR检测
• PSA检测

第十章 摄护腺癌诊断市场（依最终用户划分）

• 门诊手术中心
• 诊断中心
• 医院和诊所
• 实验室

第十一章 摄护腺癌诊断市场（依技术划分）

• 诊断影像设备
  • CT模式
  • 磁振造影技术
  • PET影像方式
  • 超音波
• 免疫检测
  • ELISA
  • RIA
• 分子诊断
  • NGS技术
  • PCR技术

第十二章 摄护腺癌诊断市场（依应用划分）

• 基因检测
• 初步诊断
• 监测和后续行动

第十三章 摄护腺癌诊断市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 前列腺癌诊断市场（依群体划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国前列腺癌诊断市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Hologic, Inc.
  • bioMerieux SA
  • QIAGEN NV
  • Laboratory Corporation of America Holdings
  • Illumina, Inc.

The Prostate Cancer Diagnostics Market is projected to grow by USD 4.33 billion at a CAGR of 14.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.45 billion
Estimated Year [2025]	USD 1.67 billion
Forecast Year [2032]	USD 4.33 billion
CAGR (%)	14.60%

Prostate cancer diagnostics sits at a pivotal intersection between rapidly advancing biomedical science and shifting clinical practice patterns. Recent years have seen diagnostic pathways evolve from a heavy reliance on single-measure screening tools to integrated strategies that combine biomarkers, molecular platforms, image-guided biopsy, and advanced imaging systems. As a result, stakeholders across clinical, commercial, and regulatory domains are reevaluating how to identify disease earlier, stratify risk more precisely, and reduce unnecessary invasive procedures while preserving or improving outcomes.

In this context, diagnostics innovation is driven by multiple technological streams. Biomarker and kit development has matured beyond basic protein assays to include genetic and molecular testing kits, which are frequently paired with sophisticated analytics. Imaging systems such as CT, MRI, PET, and ultrasound are increasingly optimized for prostate applications, and biopsy technology and technique refinement continue to shape tissue acquisition strategy. Together, these developments are reshaping clinical pathways and enabling more personalized approaches to diagnosis and management.

Transitioning from traditional paradigms, laboratories, hospitals, ambulatory surgical centers, and research laboratories are adapting workflows and capital plans to accommodate these diagnostic advances. As clinical teams integrate new tests and modalities, payers and policymakers are simultaneously reassessing coverage frameworks and care guidelines. The remainder of this executive summary synthesizes transformative shifts, structural headwinds such as tariff implications, segmentation intelligence, regional dynamics, competitor actions, and actionable recommendations for leaders navigating this evolving landscape.

How emerging multimodal diagnostic strategies, decentralized testing, and evolving reimbursement expectations are fundamentally altering prostate cancer care delivery

The diagnostic landscape for prostate cancer is experiencing transformative shifts driven by both scientific breakthroughs and operational imperatives. Molecular diagnostics, including next-generation sequencing and PCR-based assays, have transitioned from niche research tools to clinically relevant instruments that inform risk stratification and guide biopsy decisions. At the same time, advanced imaging modalities have become more tightly integrated with interventional workflows, enabling targeted biopsies and reducing diagnostic uncertainty.

Another major shift is the movement toward multimodal diagnostic algorithms that combine biomarkers, imaging, and clinical parameters to refine patient selection for biopsy and therapy. This integrative approach reduces overdiagnosis and supports more precise treatment pathways. Furthermore, decentralization of diagnostics is advancing as ambulatory surgical centers and diagnostic centers adopt point-of-care and near-patient testing options, altering referral flows and capital investment decisions made by hospitals.

Regulatory and reimbursement landscapes are also evolving to accommodate new diagnostic paradigms. Payers are increasingly focused on value-based metrics and real-world evidence, which elevates the importance of demonstrating clinical utility beyond analytical performance. Consequently, companies and clinical teams must align evidence generation with outcome-focused endpoints. Taken together, these shifts are accelerating a move from one-size-fits-all screening toward personalized diagnostic strategies that better match patient risk profiles and care goals.

Understanding the cascading operational, procurement, and supply chain consequences of cumulative tariff changes on medical diagnostics procurement and deployment

Policy changes and trade actions can exert meaningful operational pressure on medical device and diagnostic supply chains, and the aggregation of tariff adjustments in 2025 has created a set of cumulative impacts that warrant close attention. Tariff increases affecting medical equipment, reagents, and consumables tend to raise landed costs for imaging systems, biopsy devices, and kits, which in turn influences procurement cycles for hospitals, diagnostic centers, and ambulatory surgical centers. When capital budgets are constrained, decision-makers prioritize proven clinical utility and cost-effectiveness, which can slow adoption of newer devices even when they offer clear clinical benefits.

Beyond immediate cost implications, tariffs can accelerate regional sourcing strategies and supplier diversification efforts. Manufacturers and purchasers may respond by reshoring certain production activities, qualifying additional suppliers in different geographies, or seeking tariff classification optimizations to mitigate duty exposure. These responses often require lead time and investment, and they can create temporary bottlenecks in availability of specialized consumables or complex imaging components. In parallel, suppliers may adjust pricing models, renegotiate distribution agreements, or introduce bundled service offerings to preserve market access.

Importantly, clinical operations feel secondary effects as procurement uncertainty influences scheduling for capital upgrades and training programs. As a result, health systems may defer nonurgent technology refreshes, extend the lifecycle of existing assets, or adopt selective deployment strategies that concentrate new capabilities in centers of excellence. For stakeholders in the diagnostic ecosystem, proactive supply chain and policy monitoring, coupled with contingency planning, are essential to navigate the persistent ripple effects of tariff shifts.

Integrated segmentation analysis that links product, test type, end-user, technology, and application dimensions to reveal strategic priorities and clinical workflow opportunities

A nuanced view of segmentation reveals where clinical need, technology capability, and end-user context converge to create differentiated opportunities. Product type segmentation spans Biomarkers & Kits, Biopsy Needles, and Imaging Systems, with Biomarkers & Kits further differentiated into Genetic Testing Kits, Molecular Diagnostic Kits, and PSA Tests, and Imaging Systems encompassing CT Systems, MRI Systems, PET Systems, and Ultrasound Systems. This layered product taxonomy intersects with test-type segmentation, which includes Biopsy, Imaging Tests, Molecular Tests, and PSA Test, while Imaging Tests are broken into CT Tests, MRI Tests, PET Tests, and Ultrasound Tests and Molecular Tests are delineated between NGS Tests and PCR Tests. Together, product and test-type perspectives illuminate where clinical workflows are most disrupted and where integration between diagnostics and interventional procedures yields the greatest clinical return.

Examining end-user segmentation clarifies adoption pathways: Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics, and Research Laboratories each have distinct capital profiles, throughput expectations, and clinical scope, which shape technology selection and service models. Technology-focused segmentation further refines opportunity areas by distinguishing Imaging Modalities, Immunoassays, and Molecular Diagnostics, with Imaging Modalities comprising CT, MRI, PET, and Ultrasound Modalities, Immunoassays including ELISA and RIA platforms, and Molecular Diagnostics covering NGS and PCR technologies. Finally, application segmentation-Genetic Testing, Initial Diagnosis, and Monitoring & Follow-Up-maps to different clinical decision points and evidence requirements, with monitoring applications often demanding longitudinal data integration and standardized reporting.

By synthesizing these segmentation lenses, stakeholders can better target product development and commercialization strategies that account for modality-specific workflow integration, end-user procurement behavior, and the differing evidence standards across initial diagnosis versus longitudinal monitoring contexts.

Regional dynamics and infrastructure variations that determine adoption trajectories for prostate cancer diagnostics across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape adoption curves and commercialization strategies in prostate cancer diagnostics. In the Americas, health systems and private providers are responding to clinical demand for precision diagnostics by investing in molecular platforms and advanced imaging systems, while also emphasizing value-based procurement and outcome-driven evidence generation. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization, national screening policies, and variable healthcare infrastructure produce diverse adoption rhythms; certain Western European markets are early adopters of integrated diagnostic pathways, whereas other markets are focused on improving access to basic imaging and laboratory services.

Asia-Pacific reflects a mix of rapid technology adoption in urban tertiary centers and continued capacity-building in regional hospitals and diagnostic centers. Demand in that region is driven by both public health initiatives and private-sector investments in diagnostic innovation. Across all regions, ambulatory surgical centers and diagnostic centers are important vectors for dissemination of new testing modalities and for decentralizing care. Moreover, the interplay between local regulatory frameworks, reimbursement environments, and supplier footprint determines how quickly new biomarker assays, imaging systems, and molecular tests transition from clinical research to routine practice.

Consequently, companies and healthcare organizations must adopt regionally tailored strategies that account for infrastructure maturity, payer expectations, and clinical guideline adoption. Local clinical champions, targeted evidence generation, and adaptive deployment models are essential to bridge global innovation with regional implementation realities.

Competitive dynamics driven by platform innovation, strategic partnerships, and evidence generation that accelerate integrated diagnostic solutions and service-oriented commercialization

Competitive activity within the prostate cancer diagnostics ecosystem is characterized by sustained investment in platform enhancements, strategic partnerships, and evidence-building collaborations with academic and clinical centers. Established medical device and diagnostic manufacturers continue to refine imaging systems across CT, MRI, PET, and ultrasound modalities to better support prostate-specific protocols and fusion-guided biopsy workflows. At the same time, specialist firms in molecular diagnostics are expanding assay menus and streamlining workflows for next-generation sequencing and PCR-based tests to facilitate clinical integration and faster turnaround times.

Partnerships between kit manufacturers and imaging or interventional device companies are becoming more common as the market moves toward bundled diagnostic solutions that span biomarker testing, image-guided sampling, and downstream molecular analysis. Additionally, service models that pair capital equipment with training, workflow optimization, and post-sale data services are gaining traction among end-users seeking to reduce the complexity of deploying new technologies. Research laboratories and academic centers remain key collaborators for novel biomarker validation and clinical utility studies, enabling commercial players to build stronger real-world evidence packages.

Given these dynamics, successful companies prioritize cross-functional collaboration, regulatory strategy alignment, and robust post-market surveillance to demonstrate clinical value. They also invest in scalable manufacturing and diversified supply chains to mitigate policy and tariff-related disruptions while preserving market responsiveness.

Practical strategic actions for technology developers, health systems, and investors to accelerate adoption, secure supply chains, and demonstrate enduring clinical value

Industry leaders can take several actionable steps to secure clinical relevance and commercial resilience. First, align product development with clinical pathways by investing in modalities and assays that demonstrably reduce diagnostic uncertainty and downstream procedural burden. Second, prioritize partnerships with clinical centers and diagnostic networks to co-design workflows that simplify implementation and deliver measurable improvements in patient selection for biopsy and treatment decisions. By doing so, vendors can shorten adoption cycles and foster clinician buy-in.

Third, strengthen supply chain resilience through diversification of manufacturing, qualification of secondary suppliers for critical consumables, and proactive tariff and trade policy monitoring. Fourth, adopt flexible commercial models that combine capital equipment with outcome-linked services, training, and data analytics to lower adoption hurdles for end-users with constrained budgets. Fifth, invest in real-world evidence generation that aligns with payer value frameworks; pragmatic studies and registry-based evidence are particularly valuable in demonstrating clinical utility across diverse care settings.

Finally, tailor regional go-to-market strategies to local regulatory and reimbursement realities while leveraging centers of excellence to demonstrate clinical and operational value. When leaders execute these priorities, they improve the probability that new diagnostic technologies will transition smoothly from innovation to routine clinical practice.

Comprehensive multi-method research approach combining primary clinical interviews, literature synthesis, protocol case studies, and supply chain scenario analysis to ensure rigorous insights

This report synthesizes evidence from multiple methodological pillars to ensure robust, reproducible insights. Primary research activities involved structured interviews with clinical specialists, laboratory directors, and procurement leaders across hospitals, ambulatory surgical centers, diagnostic centers, and research laboratories to capture frontline perspectives on workflow integration, purchasing criteria, and clinical utility. Secondary analysis encompassed a rigorous review of peer-reviewed literature, clinical guidelines, regulatory filings, technical specifications for imaging and assay platforms, and manufacturer documentation to contextualize technological capabilities and validation pathways.

In addition, case studies and protocol reviews were used to assess how molecular diagnostics, imaging systems, biomarkers, and biopsy techniques are being operationalized in real-world settings. Supply chain and policy impacts were evaluated through scenario analysis and expert consultation to identify plausible operational responses to tariff shifts and component availability constraints. Quality assurance procedures included cross-validation of interview findings with published clinical outcomes and triangulation across multiple data sources to limit bias and ensure consistency.

The methodological approach emphasizes transparency and replicability, with documented interview protocols, source annotations, and a clear statement of inclusion criteria for secondary literature. This multi-method strategy affords a balanced view of both technological potential and the pragmatic barriers that influence adoption across varied healthcare environments.

Synthesis of clinical, operational, and policy factors that will determine whether diagnostic innovations translate into improved patient outcomes and sustainable healthcare value

Prostate cancer diagnostics is transitioning toward a more integrated, personalized, and evidence-driven model of care. The convergence of molecular testing, refined biomarker assays, and enhanced imaging systems is enabling clinicians to make more informed decisions about when to biopsy, how to target sampling, and how to monitor patients over time. Meanwhile, operational pressures such as tariff-induced supply chain adjustments and changing reimbursement expectations underscore the need for strategic agility among manufacturers and health systems.

Looking ahead, the most influential success factors will be demonstrable clinical utility, workflow-friendly solutions, and resilient commercialization strategies that respond to local infrastructure and policy realities. Collaboration between technology providers, clinical sites, and payers will be central to aligning evidence generation with the decision-making criteria that govern adoption. By focusing on integrated diagnostic pathways and pragmatic evidence, stakeholders can reduce unnecessary procedures, optimize resource use, and ultimately improve patient-centered outcomes.

In sum, the diagnostic ecosystem is positioned to deliver meaningful improvements in prostate cancer care, provided that innovation is paired with a clear articulation of clinical benefit and an operational plan that mitigates supply and policy-related risks.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of artificial intelligence and machine learning to improve prostate cancer diagnostic accuracy and reduce false positives
• 5.2. Adoption of liquid biopsy platforms for noninvasive detection of prostate cancer circulating tumor DNA biomarkers
• 5.3. Expansion of multiparametric MRI use combined with ultrasound fusion to enhance early prostate lesion characterization
• 5.4. Development and clinical validation of urinary exosome and microRNA assays for prostate cancer screening
• 5.5. Emergence of PSMA PET imaging in routine diagnostic workflows to improve metastatic prostate cancer detection
• 5.6. Regulatory approval pathways and reimbursement strategies for next generation sequencing panels in prostate diagnostics
• 5.7. Implementation of telemedicine enabled remote prostate cancer screening and real time diagnostic result interpretation
• 5.8. Growth of point of care diagnostic devices for rapid assessment of prostate specific antigen kinetics in outpatient settings
• 5.9. Collaboration between diagnostic manufacturers and academic cancer centers for discovery of novel epigenetic prostate cancer biomarkers
• 5.10. Integration of deep learning algorithms with digital pathology to automate grading and prognostic assessment of prostate biopsy specimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Diagnostics Market, by Product Type

• 8.1. Biomarkers & Kits
  • 8.1.1. Genetic Testing Kits
  • 8.1.2. Molecular Diagnostic Kits
  • 8.1.3. Psa Tests
• 8.2. Biopsy Needles
• 8.3. Imaging Systems
  • 8.3.1. Ct Systems
  • 8.3.2. Mri Systems
  • 8.3.3. Pet Systems
  • 8.3.4. Ultrasound Systems

9. Prostate Cancer Diagnostics Market, by Test Type

• 9.1. Biopsy
• 9.2. Imaging Tests
  • 9.2.1. Ct Tests
  • 9.2.2. Mri Tests
  • 9.2.3. Pet Tests
  • 9.2.4. Ultrasound Tests
• 9.3. Molecular Tests
  • 9.3.1. Ngs Tests
  • 9.3.2. Pcr Tests
• 9.4. Psa Test

10. Prostate Cancer Diagnostics Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Diagnostic Centers
• 10.3. Hospitals & Clinics
• 10.4. Research Laboratories

11. Prostate Cancer Diagnostics Market, by Technology

• 11.1. Imaging Modalities
  • 11.1.1. Ct Modalities
  • 11.1.2. Mri Modalities
  • 11.1.3. Pet Modalities
  • 11.1.4. Ultrasound Modalities
• 11.2. Immunoassays
  • 11.2.1. Elisa
  • 11.2.2. Ria
• 11.3. Molecular Diagnostics
  • 11.3.1. Ngs Technologies
  • 11.3.2. Pcr Technologies

12. Prostate Cancer Diagnostics Market, by Application

• 12.1. Genetic Testing
• 12.2. Initial Diagnosis
• 12.3. Monitoring & Follow-Up

13. Prostate Cancer Diagnostics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Prostate Cancer Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Prostate Cancer Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Roche Diagnostics International AG
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Danaher Corporation
  • 16.3.4. Thermo Fisher Scientific Inc.
  • 16.3.5. Siemens Healthineers AG
  • 16.3.6. Hologic, Inc.
  • 16.3.7. bioMerieux SA
  • 16.3.8. QIAGEN N.V.
  • 16.3.9. Laboratory Corporation of America Holdings
  • 16.3.10. Illumina, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 269. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
• TABLE 270. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
• TABLE 271. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
• TABLE 272. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
• TABLE 273. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2024 (USD MILLION)
• TABLE 278. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2025-2032 (USD MILLION)
• TABLE 279. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 280. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 281. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 282. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 283. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 284. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 285. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 286. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 287. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 288. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 289. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2024 (USD MILLION)
• TABLE 290. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2025-2032 (USD MILLION)
• TABLE 291. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
• TABLE 292. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
• TABLE 293. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 294. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 295. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
• TABLE 296. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
• TABLE 297. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
• TABLE 298. NORTH AMERICA PROSTATE CANCER DIAGN